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Abstract
Traver, Kyle Leann. M.S., Department of Neuroscience, Cell Biology and Physiology,
Wright State University, 2011.
Environmental Enrichment-Mediated Neuroprotection Against Traumatic Brain Injury:
Role of Brain-Derived Neurotrophic Factor

Each year there are over 1.7 million traumatic brain injuries (TBI) in the United States
causing long-term health deficits and significant medical costs. This growing epidemic
has led researchers to find methods for treating and preventing these injuries.
Environmental Enrichment (EE) is an innovative technique shown to improve cognitive
and functional outcomes following a TBI; however, the beneficial effects before injury
have not been established.

Brain-Derived Neurotrophic Factor (BDNF) has been

determined as a neuroprotective biomolecule in TBI. This research examined these two
protective components and their roles in TBI. It was hypothesized that BDNF mRNA
and protein levels would be elevated in animals environmentally enriched prior to TBI
compared to non-enriched animals.

Results indicated that EE applied before TBI

improved cognitive performance, but BDNF mRNA and protein levels were not elevated
significantly. These findings require further examination to determine a more definitive
relationship between these mechanisms.
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Background
Traumatic Brain Injury
The Center for Disease Control and Prevention has reported that each year
approximately 1.7 million people sustain a Traumatic Brain Injury (TBI), leading to longterm health deficits as well as significant direct and indirect medical costs1. Of these 1.7
million injuries, nearly 50,000 patients die and 90,000 individuals experience permanent
disability2. According to the World Health Organization, TBI will surpass many diseases
as the major cause of death and disability by the year 2020, with an estimated 10 million
people affected annually2. In 2000, the cost of direct and indirect care for patients
suffering from a TBI accounted for nearly 60 billion dollars in the United States alone1.
Traumatic Brain Injury is a costly, devastating condition which can generate long-lasting
social and occupational disabilities in behavior, memory, and executive function, and the
need for preventative measures against this epidemic are crucial3.
TBI is commonly categorized into three levels of severity. These levels include
mild, moderate, and severe TBI. Studies using rodents have determined that the severity
of a TBI directly correlates with the amount of histological manipulation, locomotor and
cognitive deficits seen post-injury4,5. Consequently, as TBI severity is increased, damage
to the central nervous system (CNS) tends to extend beyond the initial site of injury and
spread to other regions of the brain, particularly the hippocampus4,5. This structure is
considered part of the limbic system and is located in the basal medial part of the
temporal lobe6. The hippocampus is configured in a curved formation and is composed
of various layers of neurons6. Functions of the hippocampus include learning, memory
and integration of information. Following a TBI, these functions have been shown to be
disrupted7. Although the hippocampus may not be impacted directly during the injury,
1

the processes which occur after a TBI may result in deleterious effects on this vital brain
component.
Mechanisms of TBI
There are three main stages (acute, sub-acute & chronic) which occur following a
TBI. The first stage (acute) occurs at or near the site of injury and results in direct tissue
damage, impaired regulation of cellular metabolism, penetration of the blood brain
barrier and cellular death8,9. This stage can only be treated by preventative measures
prior to the injury, not therapeutic treatments after the TBI8. The second stage (subacute) is characterized by membrane depolarization which leads to the excessive release
of excitotoxic neurotransmitters, such as glutamate, and cytokines8. These biomolecules
act on the brain to induce cell necrosis and heighten the initial damage. The third stage
(chronic) following a TBI is delayed cell death which is caused by apoptotic influences
such as inflammation9. Each stage plays a vital role in the outcome of patients suffering
the deleterious effects of a TBI (Figure 1).
During the acute stage, direct tissue damage may occur depending on the severity
of the TBI8. This trauma can cause cellular necrosis at the site of injury and activate the
hypothalamic-pituitary-adrenal axis (HPA axis). The TBI can also disrupt the integrity of
the blood brain barrier and impair cellular metabolism8,10. Necrosis causes the release of
excitatory neurotransmitters and induces cellular metabolic failure8.

This metabolic

failure causes a loss of adenosine triphosphate (ATP) production, initiating energydependent ion pump malfunction and leading to detrimental effects on the cells of the
brain8.
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Figure 1: Mechanistic effects of a traumatic brain injury distinguished by stages.
During the acute stage, numerous physical and biochemical disruptions occur which
can lead to neuronal degeneration. These effects have the ability to carry over into the
sub-acute stage which increases degeneration by increasing apoptosis. The chronic
stage includes inflammation and advanced apoptosis, causing detrimental effects to the
CNS.
Once the HPA axis is activated, corticotrophin-releasing hormone (CRH) and arginine
vasopressin (AVP) are released from the paraventricular nucleus of the hypothalamus 5,10.
The expression of these hormones causes the release of adrenocorticotrophic hormone
(ACTH) from the pituitary, and in turn, ACTH stimulates the biosynthesis and release of
glucocorticoids (GCs), such as cortisol, from the adrenal cortex10 (Figure 2).

3

Figure 2: Normal HPA Axis Response to Stress. Once a stress transpires, the
hypothalamus and PVN activate and release CRH and AVP. These hormones activate
the anterior pituitary which leads to the release of ACTH. Discharging that hormone
causes the adrenal cortex to expel cortisol. The adrenal cortex has a negative feedback
loop to both the hypothalamus and anterior pituitary which aids in the regulation of the
system, and assists in regaining homeostasis.
Under normal conditions, these GCs act under a feedback loop with the hypothalamus to
reduce the amount of CRH produced and prevent over-activation of the system11.
Following a TBI, there is dysregulation of the HPA axis, providing persistent exposure to
GCs and numerous detrimental effects throughout the CNS10-12.
The sub-acute stage occurs hours to days following injury. During this stage,
neurons near the site of injury swell, shrink and eventually die, resulting in neuronal
degeneration8,9.

This stage is characterized by the excessive release of excitotoxic

neurotransmitters, increased lesion size and number of neuronal apoptotic cells and the
activation of voltage-dependent ion channels8,11. Fluxes in ionic concentrations cause
calcium (Ca2+) and sodium (Na+) imbalances which can result in detrimental effects
4

throughout the brain.

These effects may include the release and upregulation of

cytokines, further blood brain barrier breakdown and the need for more energy to
compensate for the dysfunction of the ionic gradients8,11,13.
The chronic stage of a TBI includes delayed cell death due to processes such as
inflammation and can occur instantaneously through weeks following insult14. This
inflammatory response involves the release of cytokines like tumor necrosis factor-α
(TNF-α), interleukin-4 and interleukin-1beta (IL-1β). These cytokines produce positive
effects including the elimination of injured and adjacent tissue as well as negative effects
like increases in apoptotic neurons in the cortex and hippocampus, activation and
accumulation of immune cells such as lymphocytes and leukocytes and impaired
neuronal function8,10,13. Studies have shown that neuronal reduction and dystrophy due to
the accumulation of immune cells may account for the long-term deficits which occur
after a TBI14-16. These effects highlight that the inflammatory process is a balance
between the cytokines which play important regulatory functions during a TBI. If this
balance becomes disrupted, detrimental effects may occur which could lead to vast
cognitive and physical deficits14. During this stage, the subfields of the hippocampus
have also demonstrated upregulation of dystrophic neurons due to inflammation, which
can lead to cell death, providing evidence of the vulnerability of the hippocampus to the
inflammatory process17.

The dentate gyrus (DG), CA1 and CA3 regions of the

hippocampus are particularly sensitive to cognitive function and learning, and damage to
these components could lead to detrimental effects (Figure 3).
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Figure 3: Hippocampus Anatomy; Paxinos, (2007) The Rat Brain

Biomolecules Involved in TBI
Other biomolecules shown to be involved in the brain’s response to TBI are
neurotrophic factors. Neurotrophic factors are a unique family of growth factors which
are locally produced in the nervous system and influence the survival, proliferation,
differentiation and death of cells in the CNS18. They are also able to mediate higherorder activities such as learning, memory and behavior18.

There are numerous

neurotrophins which have been distinguished and examples of these include: nerve
growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3)
and neurotrophin-4 (NT-4). Neurotrophic factors have the ability to influence the CNS in
diverse ways based on their availability, their functionality once phosphorylated, their
affinity to the appropriate receptors and the signaling cascades they stimulate18. These
factors have been shown to provide neuroprotective effects by influencing synaptic
plasticity and neuronal function using cytokine pairing16. Due to the fragility of this
balance and the possibility of enhanced neuroprotective effects, many studies have been
performed to determine ways which the levels of these growth factors may be regulated
following injury. One potential intervention that has been examined is environmental
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enrichment (EE), which confers numerous positive effects following an insult, including
changes in behavior and biochemical outcomes.
Environmental Enrichment
Environmental Enrichment was first established by Hebb et al. (1947) in the late
1940’s.

It is a complex sensory-motor stimulation that provides animals with an

increased opportunity for physical exercise, various learning experiences, and social
interactions which may result in a variety of neuroplastic changes in the brain19. In his
experiments, Hebb found that early experiences and environments provide permanent
effects on the problem-solving abilities of adult rats, and increasing task complexity led
to better cognitive performance19.

Hebb attributed this phenomenon to neuronal

plasticity, a term which refers to the brain transforming its elements or connectivity
because of learning and cognitive function19. This discovery led to a vast increase in
experiments which have aided in the understanding of the connection between
enrichment and plasticity.

Rosenzweig et al. (1996) determined that EE led to

measurable changes in brain chemistry and weight20. In his work, enriched rodents had
increased cortical volume, most commonly due to the development of dendritic
branching20. Enriched housing also caused increased rates of messenger RNA (mRNA)
and protein synthesis, which are required for long-term memories in various areas the
brain20,21. Following a brain insult, Rosenzweig also observed that EE improved motor
skills and increased memory performance in rodent subjects22.

In a study by

Kempermann et al. (1997), EE was found to produce a significant amount of new neurons
and a larger granule cell layer in the hippocampus compared to standard housed
animals23. All of these positive effects collectively provided support for the idea that EE
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enhances functional recovery after brain injury by increasing neurogenesis in the
hippocampus19-23.
When applied following TBI, EE facilitates learning and memory and improves
motor skills performance24,25. Models of injury include fluid percussion injury (FPI) and
controlled cortical impact (CCI).

FPI induces an injury by rapidly injecting fluid

volumes into the cranial cavity while CCI uses a pneumatic impactor to impact exposed
brain26,27.

EE attenuates some of the detrimental effects that both FPI and CCI

induce26,27.

Common trends of neuroprotection provided by enrichment after these

injuries include; attenuation of hippocampal CA3 cell loss, reduction of overall lesion
volume, induction of cell proliferation, reduction of inflammatory processes, production
of growth factors and improved cognitive performance28-30. Following an injury, rodents
exposed to EE performed better on spatial memory tasks, including the Morris Water
Maze (MWM), compared to their standard counterparts24,30. Experiment models using
rodents have also demonstrated attenuation of deficits following injury on the beam
walking task (locomotor recovery assessment) and the sawdust maze (a test of learning)
when EE was applied22. EE is consequently able to influence not only the cellular
processes when applied following injury, but also provide behavioral and physical task
enhancements.
The influence of environment on numerous biochemical and physical aspects
following an injury may be modulated by transcription factor activation as well as growth
factor expression31.

Transcription factors control and modulate the transcriptional

activity of genes and respond to changes in brain dynamics, such as a TBI. Growth
factors generally act as signaling molecules between cells and once bound to their
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specific receptors can initiate or inhibit cellular processes32. During development, growth
factors play a role in cell differentiation and neural outgrowth while in adulthood their
function switches to tissue homeostasis and neurogenesis following injury32. These
hormones are part of the neurotrophin family and are needed for the regulation and
differentiation of neurons32.
Neurotrophic Factors
Neurotrophins aid in the regulation and control of neuron development, function,
survival and plasticity33. Some of the responsibilities these regulators maintain include;
control of cellular Ca2+ homeostasis, inhibition of programmed cell death, upregulation of
enzymes for metabolism and amelioration of negative morphological and functional
effects caused by brain injury33.

Neurotrophins are synthesized and packaged into

vesicles in the soma, and are then transported to presynaptic axon terminals and released
to postsynaptic dendrites by regulated or constitutive secretion32. Most neurotrophins are
released using the regulatory pathway and require a stimulus to induce their secretion34.
Once these biomolecules are discharged, they autophosphorylate to induce functionality
and activate signaling pathways throughout the CNS using either tropomyosin-related
kinase (trk) receptors or a tumor necrosis family receptor, p75NTR 33.
The trk receptors, part of the tyrosine kinase family, are found throughout the
CNS. Once stimulated, these receptors aid in the regulation of neuronal proliferation and
survival, axonal and dendritic growth, synapse formation and function and repair of
damaged neurons33. Tyrosine Receptor Kinase (trk) A is specific for NGF while trkB
binds to both BDNF and NT-4. Brain-derived neurotrophic factor can also bind with low
affinity to the p75NTR receptor, which may cause negative effects such as apoptosis and
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long-term depression, as well as positive functions like signal transduction and cell
survival33.
Brain-Derived Neurotrophic Factor (BDNF)
Each neurotrophin influences the brain following injury, including promotion of
neuronal survival and plasticity of neuronal circuits, or neurotoxicity of the neurons from
overexposure34.

One neurotrophin in particular, BDNF, is especially effective in

promoting the survival of neurons following a TBI and is upregulated with the
application of enrichment35,36. These tendencies have led researchers to believe that
BDNF may be an important neuroprotective component in the CNS.
BDNF is a 27kDa activity-dependent modulator of neurogenesis, neuronal
structure and function, synaptic plasticity and hippocampal function37.

BDNF is

synthesized, stored and released from the glutamatergic neurons and distributed
throughout the nerve terminals and dense-core vesicles30,36,37. BDNF binds specifically
to both the trkB and p75NTR receptors 37,38.
BDNF is released following a stimulus, such as a TBI36. Once released, BDNF
can transport both anterogradely and retrogradely throughout the neurons39. This bidirectional movement of the neurotrophin allows for optimal exposure and binding with
the trkB receptor39. Binding of BDNF to its receptor activates the tyrosine kinase domain
which can then stimulate various intracellular substrates39.

One of these substrates

includes the lipid kinase phosphoinositide 3-kinase (PI3K), which upon activation
localizes to the cell membrane39,40. The PI3K pathway will cause phosphorylation of the
survival serine/threonine protein kinase Akt by recruiting it to the membrane as well40,41.
Once activated, Akt serves to phosphorylate multiple proteins and is a regulator of cell
proliferation, glucose metabolism and cell survival41. This mechanism (Figure 4) is a key
10

component and pathway for the beneficial effects that BDNF has on neuronal survival.
BDNF, as well as the other neurotrophic factors, also have the capability to stimulate the
activation of the mitogen-activated protein kinase (MAPK) pathway in hippocampal
neurons40. While this pathway is able to phosphorylate many of its downstream targets
and produce an upregulation of BDNF mRNA, Zheng et al. (2004) were able to
demonstrate that it was not as involved in the protective effects of BDNF compared to the
effects seen with the PI3K/Akt pathway40.

Figure 4: BDNF Mechanism using PI3K Pathway. BDNF causes the phosphorylation of
its trkB receptor which causes the phosphorylation of PI3K. The PI3K moves to the cell
membrane and causes the phosphorylation of Akt. Activation of Akt leads to cell survival
and increased neurogenesis.
Through the PI3K/Akt pathway, BDNF is able to induce multiple beneficial
changes in the brain not only in the neurons, but also the synapses by being a mediator of
synaptic transmission and plasticity42. BDNF is involved both pre- and post-synaptically
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and is consequently able to enhance synaptic transmission in the hippocampus by
strengthening excitatory synapses, causing long term potentiation (LTP)37,39. LTP is
believed to be the mechanism behind learning and memory37.

The induction and

maintenance of LTP is highly sustained by BDNF as shown by Bramham et al. (2005)
when LTP was unable to be induced in BDNF knock-out mice37. This study provides
evidence of the crucial involvement of BDNF in processes involving synaptic plasticity37.
BDNF is needed for neurogenesis, synaptic plasticity and hippocampal function38.
Following a TBI, changes to the CNS may prohibit BDNF from completing these crucial
tasks26,43. Pro-inflammatory cytokines can inhibit the secretion of BDNF and certain
physiological and psychological stressors have also reported decreasing the amount of
BDNF protein found in the hippocampus43. Reduction in BDNF under these conditions
can result in a loss of synaptic activity and neuronal proliferation.
Following a TBI, the levels of BDNF mRNA and protein in the neurons vary
based on the effects of the injury on the hippocampus26.

Studies have shown that

following a TBI, BDNF mRNA levels are increased contralateral to the injury for a short
period (12-36 hours after injury) of time before returning to control levels whereas these
levels are decreased significantly ipsilateral to the injury during this same time
frame26,27,43,44. These changes are seen most commonly in the CA3 and DG of the
hippocampus27. The DG granule cells show a more pronounced increase in BDNF levels
and become selectively more resilient to cell death following injury44. Increased BDNF
in the CA3 region of the hippocampal pyramidal cells also correlated with an enhanced
cell survival rate44. These findings provide further evidence of the neuroprotective role
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that BDNF plays following TBI in compensating for the loss of neurons and synapses in
the hippocampus.
Along with aiding in the recovery of hippocampal components, BDNF also plays
a role in other functional areas. When elevated, BDNF has been shown to enhance
performance on the MWM task, illustrating the ability of this neurotrophic factor to
positively influence cognitive performance51. This research group also determined that
changes induced by BDNF in synaptic plasticity, including enhanced connectivity
throughout the brain, were associated with functional recovery following brain injury51.
BDNF plays an important role in the recovery of function following a TBI, and
when EE is applied the benefits of neuroprotection are increased45,46. Enrichment alone
enhances BDNF mRNA and protein levels in the rat hippocampus, cerebral cortex and
hindbrain hours to days following application45,47. By increasing these levels of BDNF,
the amount of hippocampal neurons can elevate due to their improved survival tendencies
and increased ability to differentiate45,46. Both EE and BDNF play crucial roles in
neuronal and synaptic survival and differentiation, and plasticity throughout the CNS. By
combining these components in an appropriate paradigm, the brain may be able to
enhance its synaptic and neuronal connections, providing added neuroprotection against a
TBI.
Knowing the positive effects of both enrichment and BDNF following an injury
has fueled research of how these components work together to provide cognitive
enhancements if applied before injury.

The current research focuses on BDNF as a

neuroprotective mechanism when paired with enrichment. It is hypothesized that BDNF
mRNA and protein levels will be elevated in animals which are enriched prior to TBI
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compared to non-enriched animals.

Identifying the EE-induced mechanism behind

neuroprotection will provide cellular targets of intervention to reduce the negative effects
of TBI.
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Materials & Methods
Subjects
Animals used in this study were male Sprague Dawley rats approximately 90 days
of age from Charles River Laboratories. Forty-two animals were used for behavioral
testing while 21 were utilized for biochemical analysis. Upon arrival, animals were
separated into various housing conditions in a room with stable temperature 25C) and a
12 hour light/dark cycle. The animals were provided ad libitum access to food and water
and handled for 5 min/day or more depending on their housing condition. Animals were
weighed on a daily basis and were given 7 days to acclimate prior to testing. These
animals were part of a larger study which was focused on the effects of enrichment prior
to TBI, and in that experimental design, behavioral testing was a focal point (Figure 5).

Figure 5: Study Layout Timeline. Animals were housed appropriately 15 days prior to injury or
surgery and were then exposed to various behavioral tests before begin sacrificed at 33-days
post-injury.
15

Housing Conditions
Enriched
Environmental enrichment rats were housed 8 per cage in a large wire mesh cage
(~1m3) with a variety of items such as a running wheel, plastic tubes, ladders, ropes and
mirrors (Figure 6) for 15 days before TBI. Each day the toys were rearranged at feeding
and twice weekly the items were replaced by new toys in order to provide the animals
with novel stimuli. Enriched animals also received acrobatic training (Figure 7) and were
exposed to olfactory stimulation twice a day for 10 days (two 5-day blocks) following the
acclimation period.

Figure 6: Environmental Enrichment Cage. Animals are socially housed and given
novels toys to interact with. Other stimulators include ropes, ladders, running wheel,
olfactory stimulation and motor skills training

The EE cages were kept out of sight from the standard and control animal cages using
wall dividers. Enriched animals were subjected to a medial pre-frontal TBI following the
15-days of EE housing.
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Figure 7: Environmental Enrichment Acrobatic Training. Animals are exposed to an
obstacle course consisting of beams, ropes, and ladders which are elevated above the
ground
Standard and Control
Standard (ST-TBI) and control (Sham) animals were housed 2 per standard
polycarbonate shoebox cage for 15 days before TBI. These animals did not receive
contact with other animals or additional training and were handled with minimal contact
(5min/day) during routine cage changing. Standard animals were subjected to a medial
pre-frontal TBI following the 15-days of standard housing. The control group consisted
of sham animals which underwent anesthesia and a craniotomy but did not receive an
injury.
Controlled Cortical Impact
Enriched and ST-TBI animals were subjected to TBI via a controlled cortical
impact (CCI) device following the 15 days of appropriate housing (Figure 5). Animals
were anesthetized with isoflurane (5% induction, 2% maintenance) and secured with their
heads fixed in a horizontal position. Blood saturation of peripheral oxygen (SpO2) and
body temperature were closely monitored and maintained throughout the surgery. A
6mm craniotomy was performed 5mm anterior to bregma and the bone segment removed
was discarded.

An electrical contusion impactor (Custom Design and Fabrication,

Virginia Commonwealth University Medical Center, Richmond, Virginia) with a velocity
of 2.25m/sec and a depth of 3mm was used to inflict the TBI at the prefrontal cortex
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(total of 50msec of contact with the brain). Following the procedure, the scalp was
sutured with 7mm surgical staples. Sham controls were anesthetized and received a
craniotomy but not a CCI. After surgery and recovery, animals were returned to their
original cages and cage mates. The EE group no longer received additional enrichment
and the extra stimuli that had been dispersed in their cages were removed.

By

discontinuing EE at this stage, data would reflect the effects of enrichment prior to injury
only.

Behavioral Testing
All animals were subjected to behavioral testing starting 11 days post-injury
(Figure 5). The Morris Water Maze (MWM) was implemented to test spatial memory
and learning. Although other behavioral tests were performed, this paper will focus on
the MWM because of its specificity in learning and memory which are correlated with
hippocampal function as well as BDNF levels.

Morris Water Maze
The MWM was used 11 days after surgery to test spatial learning and memory.
Animals were placed in a 70 inch diameter dark circular tank filled with water. The tank
was divided evenly into four quadrants (A, B, C, D) with appropriate marking of the
quadrants on the top edge of the tank (Figure 8). The platform consisted of 4 inch
diameter clear plexiglass submerged 0.8 inches beneath the water level and placed
approximately 11 inches from the wall of the pool in quadrant C. Throughout the
experiment, the position of the platform was not changed.
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Figure 8: Morris Water Maze is a test of spatial learning and memory. Animals are
placed in a large pool and latency to find the hidden platform is recorded using
Ethovision Software.
Latency to find the hidden platform was recorded using Ethovision software (Noldus;
Leesburg, VA). The test was performed in two 5-day blocks over 10 days. Each animal
performed 2 trials per day, except for the 10th day during which the platform was
removed from the tank and animals were only tested once for the amount of time spent in
quadrant C. For each trial, the animal was placed in the pool in random quadrants, facing
the wall. If the animal was unable to locate the platform in 90 seconds, they were
physically guided to it and upon reaching the platform were allowed to remain there for
10 seconds. They were then removed for a 30 second interval before the start of the
second trial.
Sacrifice
Animals were sacrificed 33 days post-injury (Figure 5).

They were briefly

anesthetized with 5% isoflurane until a toe pinching test received no reaction and
decapitated via guillotine.

The brains were removed and split in half saggitally.

Alternating left and right sides were kept intact and flash frozen in isopentane. For insitu hybridization analysis, coronal sections of the brain hemispheres (14 µm) through the
prefrontal cortex and hippocampus were cut on a cryostat and stored at -20˚C. The
19

contralateral side was dissected to extract the hippocampus for Enzyme-Linked
Immunosorbent Assay (ELISA) techniques and stored at -80˚C.
Biochemical Analysis
Protein quantification techniques were used to determine the amounts of BDNF
and trkB mRNA and protein throughout various areas of the brain. In-situ hybridization
techniques were carried out at The University of Cincinnati under the supervision of Dr.
Kim Seroogy while a Promega® BDNF Immunoassay Kit was used to determine BDNF
protein concentrations in the hippocampus.

In-Situ Hybridization
Localization of BDNF and trkB mRNA was performed using in-situ hybridization
as described by Hicks et al (1998)48. Briefly, the unperfused slide-mounted sections were
pretreated by removing the slides from the -20ᵒC freezer and quickly drying them under a
stream of cold air. The slides were immersed in 4% paraformaldehyde for 10 minutes,
washed twice for 5 min in 0.1M phosphate buffer saline (PBS), washed twice for 5 min in
0.2% PBS/Glycine, washed again in 0.1M PBS, and then placed in 0.25% acetic
anhydride/0.1M triethanolamine for 10 minutes. The slides were then dehydrated using
various concentrations of ethanol, delipidated in chloroform and air dried. The BDNF
and trkB cRNA probes (Kindly provided by Christine Gall, University of CaliforniaIrvine and Kathryn Albers, University of Pittsburgh) were prepared using in vitro
transcription from a linearized cDNA construct with T3 polymerase in the presence of
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S-UTP (NEG039H, Perkin Elmer). Hybridization was performed at 60˚C for 18-24

hours using hybridization buffer [1M Tris-HCL + 0.5M EDTA + 50x Denhardt’s
Solution + 5M NaCl + 10mg/mL denatured salmon sperm DNA + 15mg/mL yeast tRNA
+ 5M DTT + 1.0x106cpm/50uL/slide 35S-labeled cRNA probe]. Following hybridization
20

treatment, slides were washed with 4x saline-sodium citrate (SSC) + 10mM sodium
thiosulfate at 37˚C twice for 30 minutes each, then incubated in ribonuclease A for 30
minutes at 45˚C. Slides were washed in 2X SSC and 0.5X SSC two times each at 37˚C
for 20 minutes, and 0.1X SSC at 37˚C for 30 minutes. Sections were dipped in dH 2O
followed by 95% EtOH, air-dried and loaded into cassettes with β-Max Hyperfilm
(Amersham). The films were exposed at room temperature for 10 days for BDNF and 7
days for trkB in order to generate film autoradiograms.

Following film development,

films were dipped in GPX developer and fixer (Kodak), air dried and then exposed in
light-tight boxes at 4˚C for 2-4 weeks.

Upon completion of the autoradiographic

development, slides were analyzed using a Nikon Optiphot-2 microscope and Scion
software (NIH). Analysis compared the density of hybridization for BDNF mRNA in the
Piriform Cortex, Prefrontal Cingulate, DG and CA3 subfields. Background hybridization
from the proximal tissue was subtracted from the hybridization in the hippocampal
subfields to obtain corrected optical density (OD) measurements. Gray scale values were
calculated by taking area of the region of interest into account as well.
Hippocampal Preparations
For immunoblot analysis of proteins, hippocampi (frozen at -80ᵒC) were thawed
on wet ice. During the thawing, 400µL of cold 0.3M sucrose buffer [102g sucrose + 4.3g
Sodium Chloride + 1.21 g Tris Base + 40mL 500mM EDTA + 40mL 500mM EGTA]
was placed in a 1.5mL microcentrifuge tube for each sample. 100µL of 0.2% Triton x100 (EW-88230-41; Cole-Parmer) and 4µL Protease Inhibitor (PI) Cocktail (P178415;
VWR) were added to the sucrose buffer and mixed thoroughly. The tissue sample was
added to the appropriate microcentrifuge tube and minced using scissors for
approximately 100 strokes. The tube was placed back on wet ice for 10 minutes to allow
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the PI to penetrate the sample fully. Following the incubation period, samples were
homogenized using the Misonix S-4000® sonicator (Fisher Scientific, Pittsburgh PA).
Timed intervals of 30 seconds were used per tube with replacement of the sample back
onto ice during settling.

Samples were sonicated until homogenous.

Following

sonication, the tubes were placed in the Legend 17R Sorvall® (Thermo Scientific,
Asheville, NC) tabletop centrifuge and spun for 8 minutes at 4ᵒC and 6000xg. The
supernatant of each sample was transferred to a fresh microcentrifuge tube (200uL per
tube) and the pellet was discarded.
BCA Protein Assay
A protein assay was performed using the instructions from the Thermo Scientific
Pierce® BCA Protein Assay Kit (23227; Fisher Scientific, Pittsburgh PA). Briefly, wash
reagent was created [5.9mL Reagent A + .118mL Reagent B]. The albumin standard
(2mg/mL) was diluted according to the test tube procedure and placed in duplicate into a
96-well plate. Supernatants were diluted 1:10 [6µL sample + 54µL milli-q H2O] and
added to the plate in duplicates. 200µL of wash reagent was introduced into each well
and incubated at 37ᵒC for 20 minutes. The plate was cooled to room temperature and
read on a spectrophotometer (Spectramax190, Molecular Devices; Silicon Valley, CA) at
a wavelength of 562nm. The results were recorded in SoftMax Pro 5.2 software for data
analysis.
BDNF Emax® ImmunoAssay
The BDNF ELISA was completed using the BDNF Emax® ImmunoAssay System
(G7611; Promega, Madison WI). Samples were normalized using Block & Sample 1X
Buffer [42.4mL of milli-q water + 10.6mL of Block & Sample 5X Buffer] to a
concentration of 6.75 mg/mL total protein and stored on ice. Plate coating was carried
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out the afternoon before running the ELISA. 10uL of anti-BDNF mAb was added to
9.99mL of carbonate coating buffer [0.025M sodium bicarbonate (AC21712-0010; Acros
Organics, New Jersey) + 0.025M sodium carbonate (AC20680-0010; Acros Organics);
adjust pH to 9.7] and mixed thoroughly by inversion.

100µL of this mixture was

dispensed into each well of a polystyrene ELISA plate (6005600; Perkin Elmer,
Waltham, Massachusetts) using a multichannel pipettor.

The plate was incubated

overnight at 4°C and the following day the wells were vigorously washed three times with
tris-buffered saline and tween-20 (TBST) [20mM Tris-HCl (IC816124; VWR) + 150mM
NaCl (VWR) + 0.05% Tween 20 (H5151; Promega)] using an automated plate washer
(ELx405 Biotek, Winooski, Vermont). 200µL of Block & Sample 1X Buffer was added
to each well and the plate was incubated for one hour. To prepare the standard, the
supplied BDNF (1 µg/mL) was diluted 1:40 [10µL of undiluted standard + 390µL of
Block & Sample 1X Buffer], then diluted to 1:2000 [10µL of the first dilution + 490µL
of Block & Sample 1X Buffer] in a fresh tube and stored at 4ᵒC. The normalized
supernatants were acid treated by adding approximately 4µL of 1N HCl to lower the pH
below 3.0, in order to dephosphorylate and to measure total BDNF protein. The samples
were incubated for 15 minutes at room temperature, and using 1N NaOH were
neutralized to a pH of approximately 7.6 and placed back on ice. Following plate
blocking, the wells were washed one time vigorously with TBST.

A serial dilution of

the standard was performed from a concentration of 125pg/mL to 1.95pg/mL, including a
blank, and samples were added to the plate in duplicate using 100µL of sample per well.
The plate was sealed using a coverslip and incubated for 2 hours with shaking at room
temperature. After incubation, the plate was vigorously washed with TBST. BDNF
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primary antibody (pAb; 1:50) was prepared and mixed [9.98mL of Block & Sample 1X
Buffer + 20µL Anti-Human BDNF pAb] and 100µL of the solution was added to each
well. The plate was sealed as before and incubated for an additional 2 hours with
shaking. After incubation, the plate was vigorously washed with TBST. 100µL of
Horseradish Peroxidase (HRP) Conjugate [9.95mL of Block & Sample 1X Buffer + 50µL
of Anti-IgY HRP conjugate] was added to each well, followed by another 1-hour long
incubation with shaking and a repeated washing. 100µL of room temperature 3,3,5,5tetramethylbenzidine (TMB) One solution (Promega) was added to each well and the
plate was covered and shaken for 10 minutes. The wells were a blue tint following this
incubation. 100µL of 1N HCL was placed into each well, which turned the solutions to a
yellow tint, and the plate was immediately read on the spectrophotometer at a wavelength
of 450nM. Data was collected for analysis using the SoftMax Pro 5.2 software.

Statistical Analysis
All measurements were analyzed with Statistical Analysis Software (SAS) and
expressed as mean ± SEM. If group (Sham, ST-TBI, and EE-TBI) was the only factor, a
one-way analysis of variance (ANOVA) was performed. If day was included as a factor,
as done for the MWM data, a mixed design ANOVA was performed. Post-hoc paired
comparisons among the groups used the Tukey procedure with a 0.05 experimentwise
error level. For completeness, two-tailed two-sample t-tests were also performed. If the
variance between the groups being tested was significantly different, approximate t-tests
were performed.
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Results
One animal from the sham control group was removed from all statistical
analysis. It was determined during sacrifice that the animal suffered a large hematoma
which resulted in various behavioral, cognitive and biochemical abnormalities. The sham
group contained n=13 for MWM, n=6 for the ELISA and n=7 for in-situ statistical
analysis after removing that animal.
MWM
Analysis of the Morris Water Maze data revealed significant differences during
the second week of testing among groups and days (Figure 9). Latency to the platform
(seconds) was used as the dependent variable in a mixed-design ANOVA with both
group and day serving as the factors.

Latency to Platform (Sec)

60
50
40
Sham
30

ST TBI
EE TBI

20
10
0

Day818
Day

Day 919

Day
Day 20
10

Day11
21
Day

Figure 9: Morris Water Maze Trends (Mean latency to find platform ± SEM). During
the last 4 days of testing (Days 18-21 Post-Injury), the EE-TBI group was able to perform
as well as the sham controls while the standard housed animals did not, suggesting that
EE is able to build resistance prior to injury

F-tests showed a significant difference among the ST-TBI, EE-TBI and Sham groups
(F2,41 = 4.56, p = 0.0162) as well as among the days (F3,121 = 4.20, p = 0.0073) but there
was not a significant group/day interaction (F6,121 = 0.41, p = 0.8697). Post hoc analysis
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by way of the Tukey method showed that ST-TBI was significantly different than both
Sham and EE-TBI. Table 1 exhibits pair-wise differences between groups at each day.

Day
8

9

10

11

Latency to Platform (sec)
Level 1
Level 2
Group Mean SEM Group Mean
Sham
20.2
6.4 ST-TBI 40.9
Sham
20.2
6.4 EE-TBI 26.0
ST-TBI 40.9
9.1 EE-TBI 26.0
Sham
15.9
4.2 ST-TBI 35.7
Sham
15.9
4.2 EE-TBI 12.2
ST-TBI 35.7
8.8 EE-TBI 12.2
Sham
13.8
2.6 ST-TBI 32.5
Sham
13.8
2.6 EE-TBI 12.6
ST-TBI 32.5
9.7 EE-TBI 12.6
Sham
14.2
2.6 ST-TBI 28.7
Sham
14.2
2.6 EE-TBI 11.2
ST-TBI 28.7
9.2 EE-TBI 11.2

Mean
SEM Diff
9.1 -20.8
5.2
-5.8
5.2
14.9
8.8 -19.7
2.5
3.7
2.5
23.5
9.7 -18.8
2.3
1.2
2.3
20.0
9.2 -14.5
1.9
3.0
1.9
17.5

Two-Tailed
Two-Sample t-test
DF
t
P
25.0 -1.78 0.0873
26.0 -0.71 0.4822
29.0 1.45 0.1582
19.9 -2.03 0.0561
26.0 0.79 0.4383
16.2 2.57 0.0203
16.1 -1.87 0.0792
27.0 0.35 0.7325
15.6 2.01 0.0619
16.2 -1.52 0.1477
27.0 0.95 0.3513
15.2 1.86 0.0817

Table 1: Results of Two-Tailed Two-Sampled t-test for the MWM
Figure 10 displays the trends of the second week of testing, excluding the last day which
was used as a probe. There were no significant differences between the standard housed
sham and the enriched conditions, but the ST-TBI group took significantly longer to
reach the platform.

Latency to Platform (Sec)
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0
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Figure 10: Morris Water Maze Results (Mean latency to hidden platform ± SEM)
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In-Situ Hybridization
BDNF and trkB mRNA levels were used as the dependent variable in a one-way
ANOVA. The factor was group and levels used were Sham, ST-TBI and EE-TBI.
Results of the f-tests are shown in Table 3.
F-test of Group

BDNF

trkB

Location

DF

F

p

Prefrontal Cingulate
Piriform Cortex
DG of Hippocampus
CA3 of Hippocampus
Prefrontal Cingulate
Piriform Cortex
DG of Hippocampus
CA3 of Hippocampus

2,18

0.01
0.18
0.99
0.68
0.13
0.06
7.54
1.42

0.9966
0.8377
0.3921
0.5215
0.8810
0.9460
0.0067
0.2769

2,18
2,18
2,17
2,13
2,13
2,13
2,13

Table 2: Results of in-situ hybridization f-test for Sham, ST-TBI and EE-TBI Groups. No
significant differences were found in the various brain regions except for trkB in the DG
(p=0.0067)
Analysis of the film autoradiograms revealed that there were no statistically significant
differences in BDNF mRNA in any of the measured brain regions among the groups;
however, in the Dentate Gyrus (DG) there was a significant difference found (F2,13=7.54,
p=0.0067) for trkB mRNA.

The Tukey procedure revealed Sham was significantly

different than ST-TBI. Using the corrected grey scale values from the densitometric
measurements, it was determined that neither housing conditions nor injury alter the
levels of BDNF (Figures 11a/11b and 12a/12b/12c) mRNA when observed 33 days postinjury.
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Figure 11: BDNF mRNA levels: (a) BDNF mRNA in Prefrontal Cingulate, (b) BDNF
mRNA in Piriform Cortex
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B) BDNF mRNA: CA3
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Mean Corrected Grey Level

A) BDNF mRNA: Dentate Gyrus
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Figure 12: BDNF mRNA Analysis: (a) BDNF mRNA Levels in Hippocampus Dentate
Gyrus, (b) BDNF mRNA in CA3 , and (c) autoradiogram image of in situ showing the
hippocampus
Throughout the various modules of the brain which were observed, the aforementioned
tests revealed that trkB mRNA levels (Figures 13a/13b and 14a/14b/14c) did not exhibit a
significant difference between groups except in the DG of the hippocampus.

28
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Figure 13: (a) trkB mRNA in Prefrontal Cingulate, (b) trkB mRNA in Piriform Cortex
A) TrkB mRNA: Dentate Gyrus
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Figure 14: trkB mRNA Analysis: (a) trkB mRNA Levels in Hippocampus Dentate Gyrus,
(b) BDNF mRNA in CA3, and (c) autoradiogram image of in situ showing the
hippocampus

Here, it was observed that there was a noteworthy distinction between the Sham and STTBI group; however, the Tukey procedure did not show significant differences between
Sham and EE-TBI for this same region. Using t-tests as shown in Table 4 (Appendix),
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ST-TBI verses EE-TBI for trkB in the DG reveals a low p-value (p=0.0357). Thus, more
analysis is required to verify this distinction and significance.
ELISA
The differences in the quantity of BDNF in the hippocampus among the varying
conditions were minimal.

BDNF protein concentration (pg/mL) was used as the

dependent variable in a one-way ANOVA with the group being the factor and did not
show a significant difference among the EE-TBI, ST-TBI, and Sham groups (F2,17=0.36,
p=0.6995). Table 2 contains paired testing among the groups
Corrected BDNF Protein Concentration (pg/mL)
Level 1
Group

Level 2

Mean SEM Group

Mean

Mean SEM

Two-Tailed
Two-Sample t-test

Diff

DF

t

p

Sham

10.9

1.8

ST-TBI

12.9

1.9

-1.9

10.0

-0.74

0.4774

Sham

10.9

1.8

EE-TBI

11.0

1.6

0.0

12.0

-0.02

0.9841

ST-TBI

12.9

1.9

EE-TBI

11.0

1.6

1.9

12.0

0.75

0.4664

Table 3: Results of Two-Tailed Two-Sample t-test for BDNF ELISA
Figure 15 illustrates the trends between the conditions and verifies that changes in BDNF
protein concentrations among the groups were negligible.

BDNF Protein Concentration (pg/mL)

BDNF ELISA
14
12
10
8
6
4
2
0
Sham

ST-TBI

EE-TBI

Figure 15: BDNF Protein Concentration Results (Mean protein concentrations ± SEM)
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Discussion
Environmental enrichment and BDNF can provide cognitive enhancements postinjury, but little is known about the mechanism of these neuroprotective effects when
applied prior to injury.

The current research sought to establish a foundational

understanding of pre-injury EE effects on post-TBI cognitive performance. In this paper,
it was hypothesized that EE, when applied prior to injury, would provide protection
against TBI and that this protection would be accompanied by elevated BDNF mRNA
and protein levels. Results determined that EE attenuated cognitive deficits when applied
prior to injury and that the beneficial effect of EE on cognitive performance was present
even without detectable changes in BDNF mRNA or protein. The following discussion
compares results from the current study to the existing body of knowledge on
neuroprotective

mechanisms,

particularly

those

involving

EE

and

protective

biomolecules like BDNF. Identifying techniques which can confer resilience to the brain
before injury and support neuronal survival could provide the framework for a new area
of study in neuroprotection.
Environmental Enrichment Improves Cognitive Performance when Applied Before TBI
EE applied prior to injury improved spatial memory in rodents compared to
standard housed animals. From our research, results for MWM testing of spatial memory
revealed that during the second week of testing (days 18-21 post-surgery), the effect of
TBI on decreasing cognitive performance was completely prevented in animals which
had been exposed to EE (Figure 9). These results are consistent with studies observing
the effects of TBI on performance as well as research exploring the effects of enrichment
when applied after injury4,27,49,50. In particular, Sozda et al. (2010) determined that
advances in performance on the MWM following TBI and EE introduction may have
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been caused by attenuation of CA3 hippocampal cell loss as well as a decrease in overall
lesion volume28. Hamm et al. (1996) and de Witt et al. (2010) found that EE applied after
injury significantly improved spatial memory performance on the MWM compared to
injured animals in standard housing which did not receive EE. Passineau et al. (2001)
also observed morphological changes near the site of injury and determined that
enrichment played a role in cell proliferation, growth factor expression and cellular
metabolism; however, the exact mechanism behind these neuroprotective effects was not
established29. These studies reiterate the original findings by Rosenzweig et al. (1996)
which determined that EE has the ability to induce neurochemical, neuroanatomical and
behavioral alterations20,30. Combined, all the findings show that EE before and after
injury may improve cognitive performance as indicated by the results in the MWM. Our
study, however, was the first to establish data which provided evidence of these
neuroprotective effects prior to TBI.
Because decreases in cognitive performance were prevented in the current
research, additional insight may be gained on which parts of the brain are affected by EE,
such as the hippocampus. The hippocampus is important in research involving TBI as
this structure is especially vulnerable to TBI and is associated to cognitive and behavioral
dysfunctions, which may include impairments in learning and memory49,50. Yu et al.
(2009) discovered that rodents displayed significant memory recall impairments in the
MWM following a CCI injury. The deficits were more prominent when the injury was
severe enough to cause damage to the hippocampus, re-establishing the importance of
this structure in learning and memory4,27,49,50. In our research, EE-TBI animals had no
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memory deficits compared to ST-TBI, suggesting EE builds resilience when applied prior
to injury to areas beyond the site of injury, such as the hippocampus.
TBI Stages Induce Various BDNF Responses
In addition to the effect EE has on cognitive performance, enrichment has
elevated BDNF levels45.

Combined, EE and elevated BDNF levels could provide

compounded neuroprotective effects towards the mechanisms following injury.
Understanding the timing of the stages following a traumatic insult is vital in considering
techniques to improve function and recovery. There are three distinct stages of TBI
response and recovery that induce a variety of biochemical changes in the CNS (Figure 1)
8,9,52,53

. In the current study, observation of BDNF levels were limited to the chronic

stage, in order to obtain behavioral data, but were not found to be significantly different
between groups. A more in-depth look at previous findings of BDNF levels during these
stages may help to explain the current results.
Acute Stage
During the acute stage of injury, BDNF levels are shown to be prominently
elevated following a short delay. Yang et al. (1996) observed BDNF mRNA and protein
level elevations occurred one hour following TBI in the hippocampus, but no changes
were observed in BDNF levels prior to this time point55. The largest increases in these
levels occurred in the granule cells of the DG followed by the CA3 region of the
hippocampus. In the DG, increased mRNA levels for the BDNF receptor, trkB, were also
observed27.

This suggests that a delay in BDNF elevation may be caused by the

biochemical processes following a TBI. These processes include elevations in Ca2+
levels as well as neuronal excitation which could activate signaling pathways, such as
cAMP response element-binding (CREB)56. Additional research completed by Hicks et al.
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(1997) and Oyesiku and colleagues (1999) reported animals exposed to a TBI
experienced large increases in BDNF mRNA and protein levels which peaked at 3-12
hours post-injury. These elevations in BDNF levels may be eliciting neuroprotective
effects throughout the brain in an attempt to counteract the effects of the mechanism of
TBI.
The effects seen during the acute phase of injury cannot be counteracted by EE
unless the enrichment is applied prior to injury. Currently, no published studies have
shown the effects of EE during the acute stage of TBI when it is applied post-injury. This
is because there is a latency for the neuroprotective effects of EE, so when applied postinjury the ‘window of opportunity’ to disrupt the cascade of detrimental effects caused by
a TBI during the acute phase is missed. The current study shows that when EE is applied
prior to TBI, changes in cognition are relevant weeks after the injury using the MWM.
Although these changes were observed during the chronic stage of TBI, disruption of the
cascade of events during the acute phase by the neuroprotection enforced by EE, and
possible increases in BDNF, may have played a role in these enhancements. Increases in
BDNF during this stage, may have improved performance on certain tasks as displayed
by BDNF knock-out (KO) mice. Bramham et al. (2005) found these rodents to have
severe deficits in MWM tasks attributed to the lack of BDNF, reiterating the role BDNF
plays in learning and memory37. Although these KO mice studies did not investigate
behavioral changes related to TBI, one can surmise that elevated levels of BDNF protects
against the detrimental effects of TBI by restoring LTP capabilities and improving
executive function.

To confirm these ideas, future studies will focus on the effects of

this EE/BDNF model during the acute phase of injury.
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Sub-Acute Stage
During the sub-acute stage of TBI, hours to days following injury, BDNF mRNA
and protein levels begin to decline. Research performed by Oyesiku and colleagues
(1999) determined BDNF was prominently elevated during the acute phase of TBI and
significant BDNF levels were still observed at 24 hours post-injury, but by 36 hours had
returned to near control levels43. Hicks et al (1997) found similar results with decreasing
BDNF and trkB levels starting at 24 hours post-injury which returned to control levels at
72 hours48. A study completed by Griesbach et al. (2002) observed the trends following a
TBI and established that BDNF mRNA was still elevated at 24 hours post-injury
compared to control subjects. These levels were not as significant as those observed
during the acute phase54. The findings above provide evidence that BDNF levels begin to
decline during the sub-acute stage which may have accounted for the results of the
current research, occurring in the chronic stage.
Environmental enrichment has been shown to enhance BDNF protein levels and
neurogenesis in the adult rat brain, especially during the sub-acute stage of TBI25,45,46. It
is determined that when EE is applied directly following injury, neurogenesis is increased
which may occur by disrupting some of the effects in these stages such as influencing the
inflammation process by decreasing the amount of pro-inflammatory cytokines45,46. By
using enrichment to enhance the amount of BDNF during the sub-acute phase, exposure
of this neuroprotective component to the hippocampus and area of injury may produce
cellular enhancements such as dendritic branching, cell proliferation, reduced
inflammation and enhanced resilience to injury27,54,57-60. Recall in this stage that cytokine
production normally increases which can lead to inflammation. Both BDNF and EE have
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been shown to decrease inflammation which may interrupt the mechanism of TBI and
account for results in this study by inducing cellular processes which could affect the
executive function of the subject. .
Chronic Stage
The current research, performed during the chronic stage, revealed no changes in
BDNF mRNA and protein levels and only one significant difference was found in the
trkB levels. These results are supported by previous research observing the trends of
BDNF during this stage. Gobbo et al. (2005) found no significant differences in BDNF
levels between enriched and standard housed injured animals at 3 weeks post-injury;
however, BDNF levels were elevated in comparison to the standard housed animals60. In
a similar study by Bindu et al. (2007) the effects on BDNF levels 3 weeks post-injury
showed that animals enriched after TBI experienced enhanced dendritic morphology and
spine density, but the levels of BDNF remained insignificant between housing
conditions63. Both of these studies demonstrate the positive effect EE may have on
neuroprotection by elevating BDNF (although not significantly) and enhancing neuronal
morphology especially when applied after injury.
The chronic stage was the only stage observed in the current study, and the
existing results of our research parallel some of the findings above. In the current study,
EE exposure prior to a TBI did not significantly elevate BDNF mRNA and protein levels
in the cortex or hippocampus when observed 33-days following the injury using the
ELISA and in-situ hybridization quantification techniques. One finding was that trkB
levels were reduced significantly in the DG for the ST-TBI group compared to the
Shams. Recall during the acute stage of injury, Hicks et al (1999) observed elevated
levels of trkB in the DG for injured animals. These levels began to decrease during the
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sub-acute stage due to cell dystrophy and inflammatory processes, which may have
resulted in the decreases seen in the current research48. These decreases in trkB receptor
may have accounted for the deficits seen in the ST-TBI group on the MWM task, a
measure of learning and memory. A reduction in receptors will limit BDNF binding sites
and thus, result in a lack of neuroprotective benefits. It should be noted that the EE-TBI
levels were not as diminished as the ST-TBI group, suggesting EE provided some
neuroprotection against cell death. There was not a significant difference found between
the EE-TBI and ST-TBI groups however, and the BDNF levels did not follow the same
trend as the trkB receptor (Figures 11a and 13a). This contradiction may be further
validated by a larger group of samples. Future investigations using a different stage of
TBI are required to observe the trends of BDNF, as well as its receptor, in
neuroprotection.
TBI Stages Induce Various BDNF Responses
All of these findings provide supporting evidence that BDNF plays a role
following a TBI, at least during a particular ‘window of opportunity’.

From the

referenced studies described above, it can be verified that BDNF has a delayed reaction
to the impact of injury and that following a certain time-point (~24-72 hours) the levels
will return to control amounts. These trends may explain why BDNF levels in our study,
observed only in the chronic stage, were not significantly different between groups.
Based on the above data, it is possible our research was past the time point of measuring
a change in the mRNA and protein intensities. Future research should include shorter
time points (possibly 1, 4, 8, 12, 24, 36, or 72 hours) of sacrifice following TBI to obtain
the mechanism of BDNF in this series of events.
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The aforementioned studies, as well as the results of our research, illustrate that
EE helps mitigate the detrimental effects of TBI and that BDNF plays a role in the
recovery of cognitive function. The exact mechanism of BDNF in repair and recovery is
unknown and requires further investigation. It is accepted that following a TBI, BDNF
increases until a particular time point to improve cognitive learning and
neurogenesis26,27,43,44.

Enrichment alone can improve cognitive function when applied

both pre- and post-injury as well as stimulate BDNF production to provide numerous
neuroprotective advantages24,25,57,59. Without fully understanding the role of BDNF and
other neuroprotective biomolecules when paired with EE, it is difficult to understand the
exact mechanism of recovery.

Hypothesized BDNF Mechanism of Recovery
Although changes in the levels of BDNF mRNA and protein were not
distinguishable in this study, BDNF may still have been a factor in neuroprotection.
Future studies using this enrichment/injury model to observe the BDNF ‘window of
opportunity’ will provide a more definitive conclusion regarding the recovery
mechanism. Until then, a possible mechanism behind this model is hypothesized based
on the literature and the current results.
From the current findings and previous research, it is hypothesized that the
proposed mechanism (Figure 16) is an appropriate model for the trends of BDNF if the
proper stages are observed. It should be noted that prior to the induction of injury, BDNF
levels may have been elevated due to animal exposure to EE. Recall that EE has been
shown to enhance BDNF protein levels and neurogenesis in the adult rat brain25,45,46.
From these findings it is also hypothesized that increased BDNF levels, induced by EE
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prior to the injury, may have caused plasticity in the brain which could result in enhanced
resilience to injury. The current study did not allow observation of the levels of BDNF
prior to injury; however, a study completed by Klein et al. (2011) has shown that there is
a strong and significant correlation between BDNF levels found in blood plasma and
BDNF in brain tissue for rats65. Therefore, future studies could observe BDNF trends
during various key experimental points, including prior to injury, to determine if BDNF
plays a role in neuroprotection both prior to and following a TBI.

Figure 16: Possible CREB Influence in TBI and BDNF Mechanism. A TBI results in HPA axis
and ATP production dysregulation which activated excess excitatory neurotransmitters as well as
NMDA receptors. The excess of neurotransmitters leads to the start of BDNF production,
activating the MAPK or PI3K pathways. The PI3K pathway causes the phosphorylation of Akt
which causes neurogenesis in the brain. Excitation of the MAPK pathway causes the increased
production of CREB, which can also be stimulated by the excess calcium produced by the
activation of the NMDA receptors. Once CREB is produced, it can fabricate elevated amount of
BDNF as well as stimulate the BCL2 family to enhance plasticity and neurogenesis in the CNS.

Once the TBI is induced, a cascade of physical and biochemical changes occur in
the CNS including activation and dysregulation of the HPA axis and ATP production
39

dysfunction5,8. These catastrophic effects may result in a loss of homeostasis throughout
the brain which then produces a compensatory response8. There is an excess release of
excitatory neurotransmitters which then activates the glutamatergic neurons to produce
BDNF. BDNF can phosphorylate and bind to its trkB receptor in order to activate
various signaling pathways, including the PI3K pathways discussed earlier. Another
pathway that BDNF can stimulate is the MAPK pathway, which then has the ability to
phosphorylate transcription factor CREB. This response is also triggered by an increase
in Ca2+. The influx in Ca2+ can also cause the phosphorylation of CREB8,9. Upon
activation, CREB regulates neuronal excitation and neurotrophic factor gene transcription
thus playing a role in neuroprotection31,64.
CREB has anti-apoptotic effects and can reduce cell death in rats introduced to
EE following an injury31,64. In the hippocampus of these rodents, Walton et al. (2000)
observed that the neurons resistant to the effects of injury had higher levels of
phosphorylated CREB56. Once phosphorylated, CREB can induce and increase BDNF
production, become co-localized with BDNF in the neurons of the hippocampus and has
the ability to regulate the transcription of BDNF directly through the MAPK and
PI3K/Akt pathways (Figure 4 & 16)64,56. Walton et al. (2000) demonstrated that Akt can
be directly phosphorylated by CREB, providing further neuroprotective effects by
continuing the cascade in the B-cell lymphoma 2 (BCL2) family which promotes cell
survival and blocks apoptosis (Figure 16)52,56.

These changes then increase BDNF

mRNA and protein levels.
This intricate series of events aids in understanding the results of the current
study. From this cascade, it can be determined that the induction of BDNF production is
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not immediate, but requires a specific series of events to occur prior to being influenced.
Yang et al. (1996) reported similar trends and found that BDNF levels were not elevated
following a TBI until one hour post-injury55.

BDNF levels will elevate and fall in a

time-dependent manner with the highest expression levels occurring once mRNA and
protein production has been initiated; however, following the acute stage of TBI, levels
will begin to decrease due to the loss of stimulation both in the PI3K pathway and CREB.
This decrease in BDNF may take between hours and days due to the extent of damage,
stimulation and inflammatory influence.
Neurotrophins may provide neuroprotective benefits during the sub-acute and
chronic stages of TBI, specifically in inflammation (not included in Figure 15). Piehl et
al. (2001) determined that neurotrophic factor production by the invading immune cells
may diminish some of the negative effects of inflammation15,16. Kerschensteiner et al.
(1999) found that immune cells, such as T cells and B cells, possess the ability to produce
BDNF52. It is therefore also hypothesized that increasing BDNF production during the
immune response may aid in minimizing neuronal damage through down-regulation of
other degenerative immune responses52. Inflammatory processes can last from days to
weeks, but the current study showed no increase in BDNF protein or mRNA levels
throughout the hippocampus.

This may have been due to a reduced inflammatory

response in the hippocampus caused by the positive influence EE may have played in
making the brain more resilient to these neurodegenerative effects. To determine if this
theory is accurate, observing alterations in cytokines using multiplexing techniques
would help to determine the role EE and BDNF have during these stages and processes.
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By observing trends of numerous biomolecules (BDNF, CREB, BCL2, Akt) in
this hypothesized model, verification of this model will be elucidated. These molecules
should be observed in both the cortex and hippocampus using techniques such as
microarray, RT-PCR, ELISA or immunohistochemistry. In addition to observing gene
expression changes, the phosphorylated proteins can be analyzed via western blot
techniques to verify activation of the proposed signaling pathways. By determining
activation of these biomolecules and expression levels, a more pronounced picture of the
mechanism of recover following TBI will be elucidated.
Verifying that this model is correct and determining the influence the BDNF has
prior to injury as well as throughout the stages of TBI will help to develop new
technologies and conditions for improved neuroprotection and neurogenesis.
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Conclusion
The hypothesis of this research was that BDNF mRNA and protein levels would
be elevated in animals which were environmentally enriched prior to TBI compared to
non-enriched animals. It was revealed that EE attenuated the injury-induced deficits in
memory when applied prior to injury. This study also revealed that exposure to EE prior
to a TBI did not elevate BDNF mRNA and protein levels in the cortex or hippocampus
when observed 33-days following the injury. There was however a significant difference
found among trkB levels in the DG of the hippocampus. The findings from this study
were critical in establishing the benefit of neuroprotection that EE provides when applied
prior to TBI.
Future research is necessary to focus on the biochemical changes of this repair
mechanism. To do so, specific times of sacrifices would be developed in order to
observe trends in BDNF and trkB during the opportune time, and determine if enriched
animals show more resilience following an injury as measured by increasing levels of
BDNF. Other studies may determine the most effective models of enrichment which will
result in enhanced resistance and optimal levels of BDNF.
Determining the underlying neuroprotective mechanisms will have a significant
impact on developing effective preventative measures to mitigate the debilitating effects
of TBI. These techniques will provide valuable understanding of the stages of TBI which
will allow for the disruption of neurodegenerative processes and improved cognitive
function. This research will continue to benefit the 1.7 million people affected yearly by
this debilitating action and has exceptional potential for aiding the resilience of soldiers
prior to engaging in war.
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Appendix
mRNA Level
Two-Tailed
Level 1
Level 2
Mean Two-Sample t-test
Group Mean SEM Group Mean SEM Diff DF
t
p
BDNF
Prefrontal
Cingulate
BDNF
Prefrontal
Piriform
BDNF
Hippocampi
DG
BDNF
Hippocampi
CA3
trkB
Prefrontal
Cingulate
trkB
Prefrontal
Piriform
trkB
Hippocampi
DG
trkB
Hippocampi
CA3

Sham
158.5 11.0 ST-TBI 159.6 22.6
Sham
158.5 11.0 EE-TBI 160.5 16.2
ST-TBI 159.6 22.6 EE-TBI 160.5 16.2

-1.1
-2.0
-0.9

12.0 -0.04 0.9655
12.0 -0.10 0.9196
12.0 -0.03 0.9744

Sham
135.4 14.8 ST-TBI 136.7
Sham
135.4 14.8 EE-TBI 127.9
ST-TBI 136.7 8.2 EE-TBI 127.9

8.2
9.5
9.5

-1.3
7.5
8.8

12.0 -0.08 0.9404
12.0 0.43 0.6779
12.0 0.70 0.4976

Sham
239.8 23.5 ST-TBI 208.8 21.9
Sham
239.8 23.5 EE-TBI 202.0 14.1
ST-TBI 208.8 21.9 EE-TBI 202.0 14.1

31.0
37.7
6.8

12.0
12.0
12.0

0.96 0.3541
1.38 0.1941
0.26 0.7994

Sham
202.0 19.6 ST-TBI 178.5 5.0 23.6
Sham
202.0 19.6 EE-TBI 190.1 11.6 12.0
ST-TBI 178.5 5.0 EE-TBI 190.1 11.6 -11.6

6.8 1.16 0.2839
12.0 0.52 0.6098
11.0 -0.86 0.4067

Sham
292.2 18.0 ST-TBI 310.9 39.1 -18.7
Sham
292.2 18.0 EE-TBI 306.3 25.9 -14.1
ST-TBI 310.9 39.1 EE-TBI 306.3 25.9
4.6

9.0 -0.46 0.6563
9.0 -0.46 0.6568
8.0 0.10 0.9250

Sham
147.6 11.4 ST-TBI 152.8 10.8
Sham
147.6 11.4 EE-TBI 150.7 11.0
ST-TBI 152.8 10.8 EE-TBI 150.7 11.0

-5.1
-3.1
2.1

9.0 -0.32 0.7538
9.0 -0.19 0.8523
8.0 0.13 0.8965

Sham
193.4 13.4 ST-TBI 134.8 9.0 58.6
Sham
193.4 13.4 EE-TBI 168.7 10.5 24.7
ST-TBI 134.8 9.0 EE-TBI 168.7 10.5 -33.9

9.0 3.74 0.0046
8.0 1.45 0.1856
9.0 -2.47 0.0357

Sham
163.3 16.0 ST-TBI 138.6
Sham
163.3 16.0 EE-TBI 144.9
ST-TBI 138.6 6.0 EE-TBI 144.9

9.0 1.55 0.1556
8.0 0.99 0.3520
9.0 -0.59 0.5704

6.0
9.4
9.4

24.7
18.3
-6.3

Table 4: In-Situ Paired Comparisons of Groups
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